Sign in

Joan T. Dea

Director at SCHWAB CHARLESSCHWAB CHARLES
Board

About Joan T. Dea

Independent director of The Charles Schwab Corporation; age 61; director since 2017 (current term expires 2027). Background: Managing Director and founder of Beckwith Investments LLC (2008–present); prior Executive Committee member at BMO Financial Group (EVP, Strategic Management & Corporate Marketing) and Partner/Director at Boston Consulting Group (financial services practice leader). She has served on the Board of Directors of Charles Schwab Bank (CSB) since 2011. Core credentials: public company leadership and governance, financial services strategy, and marketing/finance expertise .

Past Roles

OrganizationRoleTenureCommittees/Impact
Beckwith Investments LLCManaging Director (Founder)2008–presentPrivate investment/consulting; strategic capital deployment
BMO Financial GroupExecutive Committee; EVP Strategic Management & Corporate Marketing2003–2008Enterprise strategy and corporate marketing leadership
Boston Consulting GroupPartner & Director; Global Financial Services practice leader1994–2003Led advisory to banks/asset managers; operating strategy

External Roles

OrganizationRoleTenureNotes
Cineplex Inc.Director2006–May 2025Retirement effective May 2025
Performance Sports Group Ltd.Director2015–2017Prior public board
Torstar CorporationDirector2009–2015Prior public board

Board Governance

  • Committee assignments: Compensation Committee (member) and Nominating & Corporate Governance Committee (member) .
  • Independence: Board determined Dea is independent under NYSE standards; board noted her spouse serves as a trustee of a nonprofit to which the company or its affiliates have made donations and concluded independence remains intact .
  • Attendance and engagement: Board held eight meetings in 2024; each director attended at least 75% of applicable board and committee meetings. Compensation Committee held eight meetings; Nominating & Corporate Governance Committee held five meetings in 2024 .
  • Leadership context: Executive sessions of non-management directors are held regularly; Chair of Nominating & Corporate Governance (Frank C. Herringer) leads independent director sessions (Dea is a committee member, not chair) .

Fixed Compensation

Component2024 AmountTerms
Annual cash retainer (non-employee director)$100,000Standard board cash retainer
Committee membership fees$15,000 per committeeCompensation Committee member $15,000; Nominating & Corporate Governance member $15,000
CSB (bank) board cash retainerIncluded in cash totalDea’s cash column includes CSB board retainer per footnote (amount not itemized)
Equity grant (aggregate value)$215,00060% RSUs; 40% stock options; annual grants on second business day after annual meeting
Vesting (RSUs)Time-based25% on first anniversary; 25% on second; 50% on third; accelerates on death/disability/retirement
Options—term & expiryTime-basedExpire at earliest of 10 years after grant, 3 months post-service (non-retirement), or 1 year post death/disability
Exercise price policyAt/above marketUnder plan, option exercise price cannot be less than closing price on grant date
2024 Director Compensation (Joan T. Dea)Amount ($)
Fees Earned or Paid in Cash$165,000
Deferred into RSUs or Options (DCP2)— (none)
Stock Awards (RSUs grant-date fair value)$129,027
Option Awards (grant-date fair value)$86,008
Total$380,035

Performance Compensation

  • Directors do not have performance-based pay metrics. Annual director equity is time-based (RSUs and options per vesting schedule above); no director performance metrics disclosed (PBRSU metrics apply to executives, not directors) .

Other Directorships & Interlocks

  • Current/Recent public company boards: Cineplex Inc. (retiring May 2025), prior boards Performance Sports Group Ltd. and Torstar Corporation .
  • Interlocks/potential conflicts: Board considered that Dea’s spouse is a trustee at a nonprofit receiving donations from the company/affiliates; determined independence remains; ordinary-course credit transactions for directors/affiliates are permitted on market terms and reviewed under the related-party policy .

Expertise & Qualifications

  • Qualifications cited by SCHW: public company executive and board experience; financial services, banking, asset management, brokerage/investment banking; strategic planning; finance; marketing; international business; ESG .

Equity Ownership

MetricValue
Shares owned (as of March 3, 2025)22,016
Right to acquire within 60 days (likely options exercisable)31,076
Total beneficial ownership53,092; less than 1% of outstanding shares
Outstanding awards (as of Dec 31, 2024)Stock options: 40,371; RSUs: 4,708
Director stock ownership guidelineMinimum $400,000 FMV; expected within 5 years; RSUs included; options excluded
Guideline complianceAll directors compliant as of Dec 31, 2024
Hedging/pledging policyProhibits speculative trading/hedging and pledging of company securities
Section 16 filing statusNo delinquent filings disclosed for Dea in 2024 (late reports noted for others)

Governance Assessment

  • Strengths: Independent director with deep financial services and strategy background; active on Compensation and Nominating & Corporate Governance—two high-leverage committees for pay design, ESG oversight, succession, and board evaluations; strong engagement implied by committee load and board-wide attendance standards .
  • Pay/Alignment: Balanced director pay mix (cash + equity); standard vesting; ownership guideline ($400k) met at board level; prohibitions on hedging/pledging enhance alignment and mitigate risk .
  • Consultant independence and pay governance: Compensation Committee (including Dea) engages Semler Brossy; independence affirmed; peer benchmarking and risk review processes robust (signals disciplined pay governance) .
  • Potential conflicts: Spouse trustee donation relationship noted and assessed; board concluded independence under NYSE standards; related-party transactions governed by formal policy with Audit Committee review thresholds (≥$120,000) .
  • RED FLAGS: None material disclosed for Dea. No pledging/hedging permitted; no delinquent Section 16 filings for Dea; attendance threshold met; director equity not performance-linked (typical for directors) .